Attendee search 

We are a pharmaceutical startup in Memphis, Tennessee. Our focus is on pediatric drug delivery designs as we transform FDA approved therapeutic compounds into pediatric friendly drug delivery systems. We have designed several Epinephrine prodrugs to eliminate the need to use Epipen injections. We seek seed funding for organic synthesis, formulation development and CMC drug development.

Imagine a world without Musculoskeletal Disorders (MSD) like back pain and tennis elbow!

This is the vision of PRECURE! 80 million people in the EU suffer from MSD, leading to €39 billion in employer costs, and more than €80 billion in societal costs. PRECURE provide an integrated solution for insurers and companies to help prevent MSD, reduce costs and create healthier workplaces. Our smart wearables measure employees physical activities throughout the workday. The data helps the employee reduce the muscle load, enables the company to remove the causes, and for the insurer to reduce claims. This is win for the individual, employer, insurer, and society.

Eudendron is an Italian biotech company founded by Dr. Mauro Angiolini and Dr. Fabio Zuccotto. Eudendron develops anti-cancer agents for applications within the precision medicine model, adopting a tumor agnostic approach and targeting populations of patients hosting genetically defined cancers. Purpose of the company is to advance novel cancer treatments from their inception to Phase I/II. The activities of the company are also focused on the identification of novel drugs effective against protein kinase mutations responsible for clinical drug resistance. Eudendron discovered and patented a new class of highly specific inhibitors with excellent anti-cancer properties against several types of cancer cells. Patents in Europe and in USA have already been granted covering inhibitors of relevant oncology targets and their mutations. Lung and thyroid cancer, lymphoma, neuroblastoma and cutaneous cancer are diseases with unmet medical need of particular interest. Especially for neuroblastoma, the company identified drugs with a potent and specific profile. Eudendron is committed to identify Investors and/or industrial Partners to advance the pipeline programs toward the clinical stage. Basket trials will be finally designed following an agnostic clinical development.

InvivoSciences, Inc. (IVS) is a preclinical stage biotech company with a team of drug development experts, including Dr. Joseph Schlessinger, who developed various therapies including, a blockbuster drug - Sutent.
With an increasingly aging population with chronic diseases such as diabetes, heart failure is an urgent and critical challenge without an effective solution. There have been no successful phase III trials in worsening chronic heart failure or heart failure with preserved ejection fraction (HFpEF). Large clinical trials required for the heart failure trials have been the bottleneck. There is clear evidence showing that genetic factors drive heart failure development. Our mission is to cure heart failure one gene at a time.
We have leveraged our advanced artificial intelligence integrated breakthrough in precision medicine discovery platform using patient-derived human micro heart on a chip, NuHeart™, to identify and validate multiple drug pipelines rapidly as well as help us to determine biomarkers and stratify the patients for a clinical trial recruitments. Our precision heart failure pipelines are at least ten times more cost-effective to develop, especially during their clinical stages. Using our platform, we have developed two pipelines of small-molecule candidates for difficult to treat, genetically defined heart failure conditions. Our Pipelines of precision medicines have the potential to deliver better outcomes for patients fighting hard to treat heritable heart disease.
Collaborative patient-driven precision medicine-based drug development empowered with our novel platform will lead to meaningfully better outcomes for heart failure patients, which we refer to as InvivoSciences’ discovery engine to develop target therapies. Our lead program includes candidates in preclinical development for monogenetic heart failures. To date, IVS raised $8.5 Million non-dilutive funding from founders, board, commercial contracts, and grants. The funds have been used to create a portfolio of assets (breakthrough discovery platform, NuHeart™, three genetically defined disease models, current discovery programs, and a strong portfolio of patents including both US and international.
To join and support our drug discovery programs forward, InvivoSciences is seeking world-class life science investors and strategic partners for our Series A round for growth capital for $10 M in two trunches for commercial growth and accelerating our drug program.

Respinova has developed a novel non-invasive technology that aims to treat the core of the COPD pathophysiology – small airway collapse.

Respinova's solution uses unique pulses of air pressure generated by a proprietary device called PulseHaler™. ​The small airways have no cartilage structural support and are totally dependent on the tethering forces of the surrounding lung. When these forces are diminished, the small airways collapse and do not permit airflow to the gas-exchanging alveolar zone of the lung. When COPD starts, airways initially reopen on inspiration. Once the disease progresses, the airways open only on deep inspiration, and finally not at all. When the small airways collapse, not only is gas exchange is impaired, but also the cilia clearing mechanism fails, and secretions accumulate to further worsen the situation.

The small airways have little or no smooth muscle in their walls so that neither beta-adrenergic nor muscarinic drugs can open them up, even if the particles manage to be delivered to the small airways.

The PulseHaler™ generates proprietary pressure pulses that travel into the lung which propagate faster inside the airways than in the surrounding parenchyma, thereby creating multiple momentary dilating forces that help gently pry open the collapsed airways. PulseHaler™ also generates positive pressure on exhalation, which helps with airway opening. The pulses also help in smoothing and spreading the mucus lining layer on the airways walls, which assists in airway clearance and reduces the tendency of airways to re-close.

Company:
Maculus Therapeutix is a preclinical-stage biopharmaceutical company focused on finding practical solutions to treat chronic diseases of the retina and optic nerve such as wetAMD (Age related Macular Degeneration) in the Ophthalmology space with a novel tunable biodegradable proprietary product – MacuBloc™ capable of delivering any FDA approved drugs for Wet AMD to the site of the disease. With its unique suitability for targeted and extended delivery of drugs to back of the human eyes, MacuBloc™ offers significant benefits to Wet AMD patients over existing products: a single intravitreal injection that lasts an year instead of the current 10-12 monthly injections plus significant potential reduction in inflammation, infection, doctor visits and total cost of care compared to current practice.

Market:
The global market size of Age-Related Macular Degeneration (AMD) is currently $7.7B, growing at 7.6% CAGR and is expected to reach a value of $11B by 2025. Current standard of care involves 10-12 monthly injections with a 30 gauge syringe needle going through the eye sclera, often resulting post-injection pain and possible infection due to repeated injections in a small area as well as ruptured blood vessels in the sclera. By reducing the number of injections from 10+ to just ONE, MacuBloc™ formulation is likely to be a treatment of choice.

Astrom Research International is a CRO consultancy focusing on Life Science between China and Europe.